Welcome to our book review site go-pdf.online!
You may have to Search all our reviewed books and magazines, click the sign up button below to create a free account.
Current Catalog
First multi-year cumulation covers six years: 1965-70.
Uremia
None
Hypertrophic Cardiomyopathy
First described in 1907 by Schicke but recognized as a clinical entity only as recently as 1958, when Teare published the pathologic findings in patients with hypertrophic cardiomyopathy (HeM), an explosion of knowledge about this fascinating disease has occurred, which has caused a profound evolution of our understanding of its broad pathophysiologic and clinical spectrum. Progress has been particularly rapid in the past few years when M-mode echocardiography, and more recently 2-dimen sional echocardiography have been applied to the study ofHCM. In addition to new insights as to what the disease is, there has been enormous progress concerning its treatment, with the application of beta-adrenergic blocking agents and surgical relief of left ventricular outflow tract obstruction. Although these approaches have led to great strides in the symptomatic control of the disease, many patients' symptoms have remained refactory to medical and surgical therapy. Most discouragingly, sudden death still occurs, even in patients on large doses of beta-blocking agents and in patients who have had surgical relief of left ventricular outflow tract obstruction.
Myocarditis Cardiomyopathy
Primary myocardial disease, nowadays referred to as congestive or, more re cently, dilating cardiomyopathy, comprises disorders of varied etiology. Most oftenly the pathogenetic mechanism or causative agent remains unknown. The significance of inflammatory processes, i.e. myocarditis in a wider sense as the etiologic factor has been debated for many years. In a few instances, especially in children and newborns viral infections can be incriminated. In adults this etiology can be ascertained only in rare instances. And it has remained entirely uncertain if, or under which circumstances, and how often virus myocarditis can lead to a chronic disorder of the heart, namely dilated cardiomyopathy....
Metabolic Cardiomyopathy
During the last years the understanding for the aetiology of cardiomyopathies could be greatly improved. A great deal of information has accumulated in the field of inherited metabolic diseases, which provides a new basis for our understanding of many heart muscle problems and their corresponding clinical disease entities. This book is meant to give the reader a comprehensive overview of the cardiological manifestations of inborn errors of metabolism. Latest information, such as cardiomyopathy in Fabry disease or in patients with CDG-syndrome is included. It should be helpful, not only to cardiologists, paediatricians, internists and general practicioners, but also to all those interested in a better understanding of the metabolic basis of clinical disease entities.
Verhandlungen der Deutschen Gesellschaft für Innere Medizin
Solange bei der Bekämpfung von Schlafstörungen mit Arzneimitteln kein Mißbrauch getrieben wird, ist die Gefahr schädlicher Nebenwir kungen gering. Sehr häufig ist aber eine eintretende Gewöhnung durch Änderung der Reaktion des ZNS auf das Hypnotikum oder durch Be schleunigung des Abbaus der Anlaß zu einer Dosissteigerung, wodurch unerwünschte Wirkungen zunehmen. Sehr viele Schlafmittel, die nicht zur Gruppe der Barbiturate gehören, besitzen erst in höheren Dosierungen, welche die empfohlenen Dosen häufig übersteigen, eine objektiv feststellbare hypnotische Wirkung und entsprechende Nebenwirkungen. "Barbituratfrei" bedeutet daher keines falls eine bessere Verträglichkeit. Die gl...
